ABSTRACT
Aim Hepatitis B and Acquired Immunodeficiency Syndrome (AIDS) are highly endemic in Nigeria and are important causes of death and disability. Co-infection between hepatitis B virus (HBV) and Human Immunodeficiency Virus (HIV) commonly occur as both viruses share a common mode of transmission. This leads to fulminant hepatitis and liver cirrhosis depending on the stages of infection which are acute and chronic stages respectively. This study was carried to determine the prevalence of hepatitis B virus (HBV) among HIV-infected individuals in Uyo, Akwa Ibom State, Nigeria.
Methods In this study 176 HIV-infected individuals were recruited comprising 67 males and 109 females. These subjects were screened for the presence of hepatitis B surface antigen (HBsAg) using enzyme linked immunosorbent assay.
Results From those tested, 11 were positive for HBsAg giving an overall prevalence rate of 6.3%. Co-infection rate of males (8.5%) did not differ significantly (p>0.05) from that of females (6.4%). Co-infection was highest in age group 6-30 years (28.2%). In relation to marital status, singles had the higher co-infection rates (10.5%) than married subjects (4.7%). Among the different occupational groups, students had the highest co-infection rate (22.2%) and was closely followed by business (16.7%). Higher HIV/HBV co-infection was observed among those with CD4 cell count <200 cells/μl (15.4%) and those with plasma viral loads (PVL) >5001 copies/mL (13.6%).
Conclusion This study confirms the high HIV/HBV co-infection rate (6.3%) and thus, there is a need to screen all HIV-positive individuals for HBV infection. A high seroprevalence of HBV among this cohort of HIV-infected individuals contributes to the calls for pre-ART screening for HBV and the necessary paradigm shift in the ART nucleoside backbone to include agent(s) more dually effective against HIV and HBV.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NO EXTERNAL FUNDING WAS RECEIVED
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval to undertake the study was obtained from the University Research Ethics Committee of the University of Uyo Teaching Hospital (UUTH), Uyo, Akwa Ibom State, Nigeria.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
ALL DATA ARE CONTAINED IN THE MANUSCRIPT